DCAT Value Chain Insights’ Production to Prescription
DCAT
DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.
All episodes
Best episodes
Top 10 DCAT Value Chain Insights’ Production to Prescription Episodes
Goodpods has curated a list of the 10 best DCAT Value Chain Insights’ Production to Prescription episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to DCAT Value Chain Insights’ Production to Prescription for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite DCAT Value Chain Insights’ Production to Prescription episode by adding your comments to the episode page.
The Year in Review: 2020
DCAT Value Chain Insights’ Production to Prescription
12/04/20 • 21 min
Although the COVID-19 pandemic dominated the headlines in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
2020 in Review: The Top 10 Developments
1. Volume growth of pharmaceuticals declines globally.
2. New molecular entities approvals by FDA keeps pace with prior years.
3. The new AbbVie: AbbVie’s $63-Bn acquisition of Allergan.
4. Viatris launches as new company: Mylan plus Upjohn, Pfizer’s off-patent branded and generic established medicines business.
5. Gilead Sciences’ $21-Bn acquisition of Immunomedics
6. Danaher’s $21.4-Bn acquisition of GE Healthcare Life Sciences and launch of Cytiva.
7. Merck & Co.’s pending spin-off of women’s health, biosimilars & legacy products to form a new company.
8. Reshoring drug manufacturing gains policy momentum.
9. Some drug pricing reforms in the US move forward
10. Brexit uncertainty still looms.
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Company on the Move: Viatris
DCAT Value Chain Insights’ Production to Prescription
11/20/20 • 13 min
In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Rationale for the new company
- Inside the new Viatris: products
- Inside the new Viatris: manufacturing
- Inside Viatris: leadership, company structure, and cost-savings plan
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Solid-Dosage Mfg: CDMO Market and Product Trends
DCAT Value Chain Insights’ Production to Prescription
11/05/20 • 23 min
In this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- New drug approvals and solid-dosage products
- CDMOs/CMOs: inside the numbers
- Recent facility acquisitions among solid-dose CDMOs/CMOs
- Other expansions
- Catalent
- Lonza
- Metrics Contract Services
- NextPharma
- Thermo Fisher Scientific
- LGM Pharma
- Frontida BioPharm
- Adare Pharmaceuticals
- CoreRx
- Velesco Pharma
- Upperton Pharma Solutions
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Top 10 Watch List: Pharma CEOs on the Rise
DCAT Value Chain Insights’ Production to Prescription
10/23/20 • 18 min
In this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Pharma CEOs to watch in 2020
- 1. Three-way tie: Pfizer, J&J, and AstraZeneca.
- Pfizer Chairman and CEO Albert Bourla
- J&J Chairman and CEO Alex Gorsky
- AstraZeneca CEO Pascal Soriot
- 4. Moderna CEO Stéphane Bancel
- 5. Gilead Sciences Chairman and CEO Daniel O’Day
- 6. Regeneron Pharmaceuticals Co-Founder, President and CEO Leonard S. Schleifer
- 7 (tie). CureVac CEO Franz-Werner Haas and Novavax CEO and President Stanley C. Erck
- 9. Seagen (formerly Seattle Genetics) President, CEO and Chairman Clay Siegall
- 10. Genmab CEO Jan G. J. van de Winkel
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
The Pipeline Contenders: What Drugs Are Making the Mark?
DCAT Value Chain Insights’ Production to Prescription
10/09/20 • 12 min
In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside Big Pharma’s pipeline
- AbbVie
- Amgen/AstraZeneca
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Roche
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Injectable Drugs: CDMOs/CMOs and Suppliers Expand
DCAT Value Chain Insights’ Production to Prescription
09/18/20 • 28 min
In this podcast we feature a roundup of up expansions by CDMOs/CMOs and other suppliers in injectable drug development and manufacturing. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Injectable drugs and recent drug approvals
- Manufacturing expansions and technology advances
- A roundup of CDMO/CMO expansions thus far in 2020
- Vetter
- Catalent
- Grand River Aseptic Manufacturing
- CordenPharma
- Alcami
- Thermo Fisher Scientific
- Recipharm
- Samsung Biologics
- PCI Pharma Services
- WuXi Biologics
- Bushu Pharmaceuticals
- Evonik
- LSNE Contract Manufacturing
- Berkshire Sterile Manufacturing
- Integrity Bio
- Argonaut Manufacturing Services
- Suppliers of packaging materials and components for injectable drugs expand
- Corning
- Stevanato Group
- Schott
- West Pharmaceutical Services
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
API Watch: Small Molecules
DCAT Value Chain Insights’ Production to Prescription
09/04/20 • 19 min
In this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Small-molecule new drug approvals thus far in 2020
- Small molecules and blockbuster potential
- Novo Nordisk’s Rybelsus
- Bristol-Myers Squibb’s Zeposia
- Novartis’ inclisiran
- Gilead Sciences’ filgotinib
- Akebia Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat
- Biohaven Pharmaceuticals’ Nurtec
Sponsor: Dr. Reddy’s Laboratories
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
The Top 10 Deals for Pharma Innovation
DCAT Value Chain Insights’ Production to Prescription
08/24/20 • 18 min
In this podcast we feature the top 10 deals thus far in 2020 and which pharma/biopharma companies are rising to the top. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
1. Novartis’s $9.7-billion acquisition of The Medicines Company and Blackstone’s $2-billion investment in Alnylam Pharmaceuticals.
2. Daiichi Sankyo’s and AstraZeneca’s $6-billion ADC collaboration. Pairing
3. Gilead Sciences’ $4.9-billion acquisition of Forty Seven Inc.
4. Genmab’s $3.9-billion cancer antibody pact with AbbVie.
5. Sanofi’s pending $3.69-billion acquisition of Principia Biopharma.
6. Amgen’s $3.2-billion combined deals with BeiGene .
7. Astellas’s $3-billion acquisition of Audentes Therapeutics.
8. Sangamo Therapeutics’ $2.7-billion licensing pact with Biogen.
9. Merck & Co’s $2.7-billion acquisition of ArQule .
10 (Tie): Merck & Co.’s $2.5-billion research pacts with Taiho Pharmaceutical and Astex Pharmaceuticals, subsidiaries of Otsuka .
10 (Tie): Sanofi ’s $2.5-billion acquisition of Synthorx .
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Re-configuring Global Pharma Supply Chains
DCAT Value Chain Insights’ Production to Prescription
07/10/20 • 17 min
In this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- A plan for addressing supply-chain vulnerabilities in the US
- Legislative proposals in the US
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Mid-Year CDMO Review: COVID-19 Vaccine Manufacturing and M&A
DCAT Value Chain Insights’ Production to Prescription
06/11/21 • 16 min
What have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- CDMOs and COVID-19 vaccine manufacturing
- Potential implications of increased injectables capacity
- CDMO M&A remains robust
- Cell and gene therapies: a major source of CDMO M&A
- Private equity and CDMO M&A
- Largest deal thus far: Thermo Fisher Scientific/PPD
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Show more best episodes
Show more best episodes
FAQ
How many episodes does DCAT Value Chain Insights’ Production to Prescription have?
DCAT Value Chain Insights’ Production to Prescription currently has 47 episodes available.
What topics does DCAT Value Chain Insights’ Production to Prescription cover?
The podcast is about And, Development, Podcasts, Manufacturing, Science, Business and Pharmaceutical.
What is the most popular episode on DCAT Value Chain Insights’ Production to Prescription?
The episode title 'Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead' is the most popular.
What is the average episode length on DCAT Value Chain Insights’ Production to Prescription?
The average episode length on DCAT Value Chain Insights’ Production to Prescription is 18 minutes.
How often are episodes of DCAT Value Chain Insights’ Production to Prescription released?
Episodes of DCAT Value Chain Insights’ Production to Prescription are typically released every 14 days, 3 hours.
When was the first episode of DCAT Value Chain Insights’ Production to Prescription?
The first episode of DCAT Value Chain Insights’ Production to Prescription was released on Feb 14, 2020.
Show more FAQ
Show more FAQ